Physician profile
Nancy E Mills
NPI 1992775795
$5,287.85
in general payments reported to CMS, 2019-2025
12 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $1,750 · 2021: $897 · 2022: $243 · 2023: $624 · 2024: $981 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.29 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $2,521.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $921.29 | 2021-2025 | Lynparza, Enhertu, Datroway |
| Daiichi Sankyo INC. | $674.94 | 2021-2024 | Enhertu |
| Amgen INC. | $257.85 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $250.00 | 2023-2024 | Keytruda |
| Genentech USA, INC. | $150.00 | 2019 | |
| Genmab U.S., INC. | $125.13 | 2024 | Tivdak |
| Novartis Pharmaceuticals Corporation | $125.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2020 | |
| Puma Biotechnology, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.